Preclinical investigations and first-in-human application of ¹⁵²Tb-PSMA-617 for PET/CT imaging of prostate cancer.

ABSTRACT:

Background

For almost a decade, terbium radioisotopes have been explored for their potential theragnostic application in nuclear medicine: ¹⁵²Tb and ¹⁵⁵Tb are the radioisotopes identified for PET or SPECT imaging, while ¹⁴⁹Tb and ¹⁶¹Tb have suitable decay characteristics for α- and combined β^-/Auger-e^--therapy, respectively. In the present study, the application of ¹⁵²Tb, in combination with PSMA-617 for imaging of prostate-specific membrane antigen (PSMA)-positive prostate cancer, was demonstrated in a preclinical setting and in a patient with metastatic castration-resistant prostate cancer (mCRPC).

Results

¹⁵²Tb was produced at the ISOLDE facility at CERN/Geneva, Switzerland, by spallat

SUBMITTER: Muller C 

PROVIDER: S-EPMC6658632 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature